Mirum Pharmaceuticals, Inc.

MIRM

N/A

NASDAQBiotechnology🇺🇸North America355 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

25w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Blinded CDCA 250 mg TID	Phase 3	CTX	-
Cholic acid	Phase 3	Inborn Errors of Bile Acid Synthesis	-
Cholic Acids	Phase 3	Infantile Refsum's Disease	-
Placebo	Phase 2	Alagille Syndrome	-
LUM001	Phase 2	Alagille Syndrome	-
Maralixibat	Phase 2	Biliary Atresia	-
Ursodeoxycholic Acid	Phase 2	PBC	-
Low dose of MRM-3379	Phase 2	Fragile X Syndrome	-
Volixibat	Phase 2	Primary Biliary Cholangitis	-
LUM001 (Maralixibat)	Phase 2	Alagille Syndrome	-

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

June 2026~Placebo

Primary completion for Placebo trial (NCT04663308) in Primary Sclerosing Cholangitis

Phase 2

June 2026~Volixibat

Primary completion for Volixibat trial (NCT04663308) in Primary Sclerosing Cholangitis

⭐Phase 3

October 2026~Maralixibat

Primary completion for Maralixibat trial (NCT06553768) in Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

Regulatory Approvals

MIRM News